Skip to main content

Table 2 Patient characteristics in the included studies

From: Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

Author Mean age (range) Initial stage (%) Histology (ductal/lobular, %) Grade (I/II/III, %) Receptor phenotypes
(ER+/PR+/HER2+, %)
Subtypes (luminal A/B/HER2/TN, %) pCR (%)
Akimoto [12] 53.9 I/II/III: 8/73/19 NR 4/28/67
Unknown: 2
69/57/28 ER+/HER2−: 53
HER2+: 28
TN: 19
23
Champion [13] 51 ± 12.7 all T4d, M0 95/0 9/30/61 HR+:43
HER2+: 22
HR+/HER2−: 48
HR−/HER2+: 22
TN: 30
22
Chen [14] 51 II/III: 14/86 NR NR 56/37/28 ER+/HER2−: 43
HER2+: 28
TN: 29
17
Dunnwald [15] NR T1/2/3/4: 3/21/57/19
N0/1/2/3: 19/61/17/3
92/8 NR 55/45/26 NR 28
Emmering [16] 48 (29–63) IIB: 15
IIIA/B/C: 43/30/13
70/13 NR NR NR 20
Garcia Vicente [17] 52.6 ± 12.7 (25–80) NR 92/8 NR NR 10/55/12/23 NR
Groheux [18]* 50.4 ± 11.7 (30–82) T1/2/3/4: 2/39/39/20
N0/1/2/3: 39/48/10/3
90/7 6/68/26 100/67/0 ER+/HER2−: 100 5
Groheux [19] 51 (27–78) IIA/B: 27/23
IIA/B/C: 23/22/5
94/0 0/10/88 0/0/0 TN: 100 37
Humbert [20] NR T1–2/3: 88/12
N0/1–2: 38/62
90/10 5/80/15
Unknown: 2
98/91/0 HR+/HER2−: 100
Luminal A/B: 5/76
2
Humbert [21] 46 (26–85) IIA/B: 35/30
IIIA/B/C: 9/4/22
98/2 0/18/78 0/0/0 TN: 100 43
Hyun [22] 44 (22–68) II/III: 32/68 95/2 NR HR+: 51
HER2+: 27
HR+/HER2−: 40
HR−/HER2+: 16
TN: 33
17
Ishiba [23] 54 (30–75) II/III: 82/18 95/1 45/24/24
Unknown: 7
NR luminal A and B 65
luminal HER2 7
HER2: 12
TN 16
17
Jung [24] 44 (21–64) II/III: 56/44 NR NR 56/36/41 NR T/N: 15/29
Kim [25] 46.5 (27–72) II/III: 80/20 100/0 21/44/35 NR HR+/HER2–55
HER2+: 27
TN: 18
16
Kitajima [26] 53.6 ± 12.4 (29–77) I/II/III: 7/48/45 96/0 12/11/32
Unknown: 45
50/38/45 14/39/20/27 34
Kiyoto [27] 54 (31–71) IIA/B: 16/34
IIIA/B/C: 22/3/25
94/0 16/37/47 0/0/0 TN:100 22
Kolesnikov-Gauthier [28] 49 ± 9 (30–70) T2/3: 60/37
N0/1/2: 58/37/3
97/3 5/42/27
Unknown: 27
53/37/20 NR 22
Lee [29] 46.1 (26–73) T1/2/3/4: 14/70/10/6
N1/2/3: 61/14/25
NR 11/33/22
Unknown: 33
41/33/48 25/20/31/24 20
Lian [30] 48.1 (28–76) II/III 74/26 100/0 NR 58/50/44 1/58/20/21 36
Lim [31] 48 (26–68) T1/2/3/4: 9/41/33/17
N0/1/2/3: 4/20/54/13
93/4 NR 54/74/35 NR NR
Zucchini [32] 49 (31–72) II/III/IV: 50/38/12 NR NR NR ER+/HER2−: 52
HER2+: 23
TN: 25
22
  1. *Age and clinical stages were only available for whole study population, whereas survival analysis was performed in a subset of subjects
  2. Median
  3. T and N represent pCR rate in the primary tumour and axillary node, respectively
  4. ER oestrogen receptor, HR hormone receptor, HER2 human epidermal growth factor receptor 2, NR not reported, pCR pathological complete response, PR progesterone-receptor, TN triple-negative